Edgar Filing: Arch Therapeutics, Inc. - Form 8-K

Arch Therapeutics, Inc. Form 8-K July 31, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2015

ARCH THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada 000-54986 46-0524102 (State or other jurisdiction of incorporation) (Commission (I.R.S. Employer File Number) Identification No.)

235 Walnut Street, Suite 6
Framingham, Massachusetts
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (617) 431-2313

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: Arch Therapeutics, Inc. - Form 8-K

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- "Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- "Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

- Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
 5.02 Compensatory Arrangements of Certain Officers.
- (e) Adjustments to Annual Base Salary for the Company's Chief Financial Officer

On July 27, 2015, Arch Therapeutics, Inc. (the "Company") and Richard E. Davis, the Chief Financial Officer of the Company, entered into an amendment to Mr. Davis's Executive Employment Agreement dated July 7, 2014 (the "Amendment"). Pursuant to the Amendment, which was subject to and became effective upon its approval by the the Board of Directors (the "Board") of the Company, Mr. Davis' annual base salary was increased by \$50,000 to \$250,000, effective as of July 1, 2015. The Board unanimously approved the Amendment.

Item 9.01 Financial Statements and Exhibit

(d) Exhibits

Exhibit Description

First Amendment to Executive Employment Agreement, dated July 27, 2015, by and between Arch Therapeutics, Inc. and Richard E. Davis

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARCH THERAPEUTICS, INC.

Dated: July 31, 2015 By:/s/Terrence W. Norchi, M.D.

Name: Terrence W. Norchi, M.D. Title: President, Chief Executive

Officer

Exhibit List

Exhibit Description

First Amendment to Executive Employment Agreement, dated July 27, 2015, by and between Arch Therapeutics, Inc. and Richard E. Davis